Drug intelligence / Profile preview

probiotic CNCM I-4035 + probiotic CNCM I-4036

Development stage: Unknown
Lead developer: Universidad de Granada
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

The combination of probiotic CNCM I-4035 (*Bifidobacterium breve*) and probiotic CNCM I-4036 (*Lactobacillus rhamnosus*) consists of two bacterial strains originally isolated from the feces of exclusively breast-fed infants and deposited in the Collection Nationale de Cultures de Microorganismes (CNCM) at the Institute Pasteur. This combination is primarily investigated for its immunomodulatory and anti-inflammatory effects. Preclinical studies have demonstrated its potential in modulating gut microbiota, influencing macrophage polarization, and reducing systemic inflammatory markers such as serum lipopolysaccharide (LPS) levels. It has been specifically evaluated for conditions like non-alcoholic fatty liver disease (NAFLD), hepatic steatosis, and obesity-related inflammation. Clinical safety and tolerance have been established in healthy volunteers, often as part of a three-strain probiotic mixture that includes *Lactobacillus paracasei* CNCM I-4034.

Other names: Bifidobacterium breve CNCM I-4035 + Lactobacillus rhamnosus CNCM I-4036

Beyond the preview

Go deeper on probiotic CNCM I-4035 + probiotic CNCM I-4036.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on probiotic CNCM I-4035 + probiotic CNCM I-4036.

Explore the full profile